Suchergebnisse - "Frisell, Thomas"

PubPharm (6)

1

Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis : A Nationwide Cost-Effectiveness Study

enthalten in: Annals of neurology | 2024

von Alping, P. | Neovius, M. | Piehl, F. | +1

2

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

enthalten in: Annals of neurology | 2020

von Alping, P. | Askling, J. | Burman, J. | +13

3

enthalten in: Annals of neurology | 2016

von Alping, P. | Frisell, T. | Svenningsson, A. | +1

CommentOn: Ann Neurol. 2016 Jun;79(6):950-8. - PMID 27038238

4

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

enthalten in: Annals of neurology | 2016

von Alping, P. | Frisell, T. | Novakova, L. | +9

CommentIn: Ann Neurol. 2016 Nov;80(5):791-792. - PMID 27553863

5

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

enthalten in: Annals of neurology | 2016

von Alping, P. | Frisell, T. | Novakova, L. | +9

6

enthalten in: Annals of neurology | 2016

von Alping, P. | Frisell, T. | Svenningsson, A. | +1

1
[1]